Arax Advisory Partners’s LB Pharmaceuticals LBRX Stock Holding History

Arax Advisory Partners’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$357	Buy	+11	New	+$323	﹤0.01%	5046

Other funds holding LBRX

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

JP Morgan Chase

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Spruce Street Capital New York $510M AUM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Arax Advisory Partners's LBRX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 11 shares worth $357. The stake represents ﹤0.01% of the portfolio and ranks #5046 among its holdings.

115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

Arax Advisory Partners held 11 shares of LB Pharmaceuticals worth $357 as of Q2 2026.
LB Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
LB Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5046 holding.
115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.